JP2019526580A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526580A5 JP2019526580A5 JP2019512191A JP2019512191A JP2019526580A5 JP 2019526580 A5 JP2019526580 A5 JP 2019526580A5 JP 2019512191 A JP2019512191 A JP 2019512191A JP 2019512191 A JP2019512191 A JP 2019512191A JP 2019526580 A5 JP2019526580 A5 JP 2019526580A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- seq
- administered
- weeks
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383140P | 2016-09-02 | 2016-09-02 | |
| US62/383,140 | 2016-09-02 | ||
| PCT/US2017/049817 WO2018045267A1 (en) | 2016-09-02 | 2017-09-01 | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526580A JP2019526580A (ja) | 2019-09-19 |
| JP2019526580A5 true JP2019526580A5 (enExample) | 2020-10-15 |
Family
ID=59887395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512191A Pending JP2019526580A (ja) | 2016-09-02 | 2017-09-01 | 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10307477B2 (enExample) |
| EP (1) | EP3506937A1 (enExample) |
| JP (1) | JP2019526580A (enExample) |
| CN (1) | CN110494159A (enExample) |
| AU (1) | AU2017318689A1 (enExample) |
| CA (1) | CA3035759A1 (enExample) |
| WO (1) | WO2018045267A1 (enExample) |
| ZA (1) | ZA201901899B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3197489T (pt) * | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana |
| CN108368157B (zh) | 2015-12-15 | 2022-04-15 | 扬森疫苗与预防公司 | 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法 |
| MX392862B (es) | 2016-06-16 | 2025-03-24 | Janssen Vaccines & Prevention Bv | Formulación de vacuna contra el vih. |
| CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
| PT3512543T (pt) | 2016-09-15 | 2020-10-13 | Janssen Vaccines & Prevention Bv | Trímero que estabiliza mutações das proteínas do envelope do hiv |
| WO2018229711A1 (en) | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| CA3069052A1 (en) | 2017-07-19 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations |
| WO2019055888A1 (en) * | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020237052A1 (en) * | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| AU2020279988A1 (en) * | 2019-05-22 | 2021-12-23 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| JP2023521194A (ja) | 2020-04-13 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用 |
| US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
| WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022084333A1 (en) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Hiv vaccine regimens |
| WO2022272275A1 (en) * | 2021-06-25 | 2022-12-29 | Janssen Vaccines & Prevention B.V. | Combinations of vaccines and neutralizing antibodies for treating human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| WO2024036217A2 (en) * | 2022-08-09 | 2024-02-15 | Fred Hutchinson Cancer Center | Immunization strategies to more naturally guide the maturation of antibodies against human immunodeficiency virus (hiv) in hiv-infected subjects |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| WO2001019958A2 (en) | 1999-09-17 | 2001-03-22 | Dana-Farber Cancer Institute, Inc. | Stabilized soluble glycoprotein trimers |
| WO2002042480A2 (en) | 2000-11-23 | 2002-05-30 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| JP4500049B2 (ja) | 2001-12-04 | 2010-07-14 | バヴァリアン・ノルディック・アクティーゼルスカブ | フラビウイルスｎｓ１サブユニットワクチン |
| PT1497438E (pt) | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Meios e métodos para a produção de vectores de adenovírus |
| WO2004044155A2 (en) | 2002-11-07 | 2004-05-27 | Beth Israel Deaconess Medical Center | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| US7901690B2 (en) | 2002-12-03 | 2011-03-08 | University Of Massachusetts | Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods |
| EP2363143A3 (en) | 2003-03-28 | 2012-02-15 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
| EP1667631A4 (en) | 2003-09-15 | 2010-04-14 | Novartis Vaccines & Diagnostic | COMBINATION PATHS FOR GENERATING IMMUNE RESPONSES |
| WO2005052119A2 (en) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants of immune response |
| EP1766097A4 (en) | 2004-06-15 | 2008-03-19 | Progenics Pharm Inc | HIV-1 NEUTRALIZING ANTIBODIES INDUCED BY A TRIMER HIV-1 HYLLGLYCOPROTEIN COMPLEX |
| EP1784416B1 (en) | 2004-07-16 | 2011-10-05 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccines against aids comprising cmv/r nucleic acid constructs |
| KR101253363B1 (ko) | 2004-10-13 | 2013-04-15 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 개선된 아데노바이러스 벡터 및 그것의 용도 |
| CA2656741A1 (en) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| CA2620874A1 (en) | 2005-08-23 | 2007-03-01 | The Regents Of The University Of California | Polyvalent vaccine |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| CA2655934A1 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
| CA2667358A1 (en) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
| WO2008140579A2 (en) | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
| HUE031411T2 (en) | 2007-03-02 | 2017-07-28 | Glaxosmithkline Biologicals Sa | New Methods and Preparations |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| HRP20181776T1 (hr) | 2008-11-18 | 2019-02-08 | Beth Israel Deaconess Medical Center, Inc. | Antivirusna cjepiva sa poboljšanom staničnom imunogenosti |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| US9241986B2 (en) | 2010-01-04 | 2016-01-26 | Kj Biosciences Llc | DPS fusion proteins for use in vaccines and diagnostics |
| NZ600629A (en) | 2010-01-28 | 2014-12-24 | Bavarian Nordic As | Vaccinia virus mutants containing the major genomic deletions of mva |
| EP4549461A3 (en) | 2010-08-31 | 2025-08-06 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
| WO2013036791A2 (en) | 2011-09-09 | 2013-03-14 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2766037A4 (en) | 2011-10-12 | 2015-08-05 | Scripps Research Inst | HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF |
| WO2014047261A1 (en) | 2012-09-19 | 2014-03-27 | Beth Israel Deaconess Medical Center, Inc. | Viruses associated with immunodeficiency and enteropathy and methods using same |
| WO2014078688A2 (en) | 2012-11-16 | 2014-05-22 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
| SG10201705880QA (en) | 2013-01-07 | 2017-08-30 | Beth Israel Deaconess Medical Ct Inc | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| US10248758B2 (en) | 2013-02-07 | 2019-04-02 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
| JP2017507672A (ja) * | 2014-02-28 | 2017-03-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法 |
| WO2016037154A1 (en) | 2014-09-04 | 2016-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant hiv-1 envelope proteins and their use |
| PT3197489T (pt) * | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| CN108368157B (zh) | 2015-12-15 | 2022-04-15 | 扬森疫苗与预防公司 | 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法 |
| MX392862B (es) | 2016-06-16 | 2025-03-24 | Janssen Vaccines & Prevention Bv | Formulación de vacuna contra el vih. |
| CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
| PT3512543T (pt) | 2016-09-15 | 2020-10-13 | Janssen Vaccines & Prevention Bv | Trímero que estabiliza mutações das proteínas do envelope do hiv |
-
2017
- 2017-09-01 CN CN201780067261.7A patent/CN110494159A/zh active Pending
- 2017-09-01 US US15/693,650 patent/US10307477B2/en active Active
- 2017-09-01 JP JP2019512191A patent/JP2019526580A/ja active Pending
- 2017-09-01 AU AU2017318689A patent/AU2017318689A1/en not_active Abandoned
- 2017-09-01 EP EP17768310.9A patent/EP3506937A1/en not_active Ceased
- 2017-09-01 WO PCT/US2017/049817 patent/WO2018045267A1/en not_active Ceased
- 2017-09-01 CA CA3035759A patent/CA3035759A1/en active Pending
-
2019
- 2019-03-27 ZA ZA2019/01899A patent/ZA201901899B/en unknown
- 2019-04-16 US US16/385,062 patent/US10525123B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526580A5 (enExample) | ||
| Hanke et al. | Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | |
| Ertl et al. | Novel vaccine approaches | |
| Moore et al. | Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria | |
| Hasanpourghadi et al. | COVID-19 vaccines based on adenovirus vectors | |
| Bailey | An assessment of the role of chimpanzees in AIDS vaccine research | |
| JP2017515508A5 (enExample) | ||
| JP2019123734A (ja) | 免疫応答の増進を目的とする方法及び組成物 | |
| JPWO2012053646A1 (ja) | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター | |
| JP2019505560A5 (enExample) | ||
| WO2020247547A1 (en) | Cancer vaccine compositions and methods for use thereof | |
| JP2016074727A5 (enExample) | ||
| CA2764903C (en) | Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens | |
| WO2002068654A2 (es) | Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana | |
| Ishii et al. | Development of an AIDS vaccine using Sendai virus vectors | |
| US11274282B2 (en) | Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen | |
| Kaulfuß et al. | Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery | |
| JP2007505923A (ja) | Ｄｎａワクチン組成物およびその使用方法 | |
| Bayer et al. | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes | |
| US20100322965A1 (en) | Viral vaccine vectors | |
| Ngu et al. | Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells | |
| JP7314441B2 (ja) | 選択的ｃｄ８陽性ｔ細胞誘導ワクチン抗原 | |
| CN110382518A (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| CN101394868A (zh) | 重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法 | |
| Hanke | Vehicles for Genetic Vaccines Against Human Immunodeficiency Virus Induction of T Cell-mediated Immune Responses |